TARS

As of 2026-10-26, TARS scores 40out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. TARS trades at $70.03, within its fair-value band.

TARS scores 40 out of 100 on QNTM's five-factor model — a low-conviction reading — at 40 the factor profile is among the weaker names in the universe. Its strongest factor is volume at 45 (middling), where trading volume confirms genuine accumulation, followed by momentum at 44. The weakest is sentiment at 26, where sentiment signals are working against it. Among Healthcare stocks it sits in the lower 17% of Healthcare names by composite.

On valuation, TARS is priced around the middle of its recent range. The blended composite before the macro overlay was 40. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on TARS, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where TARS sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for TARS runs $50.59–$83.94. Current price $70.03 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.